Press coverage about Apricus Biosciences (NASDAQ:APRI) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apricus Biosciences earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1175925186328 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Apricus Biosciences (APRI) traded up $0.08 during trading hours on Tuesday, hitting $1.68. 237,800 shares of the stock traded hands, compared to its average volume of 642,164. Apricus Biosciences has a one year low of $0.86 and a one year high of $4.07.
Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.15). During the same quarter in the prior year, the company posted ($0.19) EPS. sell-side analysts expect that Apricus Biosciences will post -0.6 earnings per share for the current year.
A number of brokerages recently issued reports on APRI. HC Wainwright reiterated a “buy” rating and issued a $4.50 target price on shares of Apricus Biosciences in a research report on Tuesday, September 5th. Zacks Investment Research lowered shares of Apricus Biosciences from a “buy” rating to a “sell” rating in a research report on Tuesday, November 7th.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-apricus-biosciences-apri-stock-price.html.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.